Taiwan considers expanding Hepatitis B drug coverage, expecting 30,000 patients to benefit

Taiwan is planning to expand the eligibility criteria for Hepatitis B (HBV) antiviral drug coverage under its National Health Insurance program. The National Health Insurance Administration is reviewing proposals that could extend treatment to an estimated 17,000 to 30,000 patients currently not covered.

The proposed revisions aim to include individuals with liver fibrosis at stage F2 or higher, along with those whose HBV DNA levels are at or above 2,000 IU/mL and whose ALT levels exceed the normal range by more than double. Additionally, HBV patients diagnosed with liver cancer may also become eligible for long-term antiviral therapy.

“

We are planning to strengthen the early detection mechanism for non-viral hepatitis liver cancer.

These efforts build upon Taiwan's significant achievements in combating Hepatitis C (HCV). The island has already applied for WHO certification for the elimination of HCV and has received positive feedback from international experts. Minister of Health and Welfare, Shih Chung-liang, highlighted Taiwan's success in meeting WHO targets for HCV prevention five years ahead of schedule.

Looking ahead, Taiwan aims to further reduce the mortality rate from liver cancer by advancing HBV treatment and improving early detection of liver cancer. The Ministry of Health and Welfare is also exploring risk assessment models for non-viral liver diseases, such as metabolic syndrome and fatty liver, to enhance early detection strategies for liver cancer.

“

The National Health Insurance Administration is required to accelerate the review of current coverage regulations, referencing international treatment guidelines, health technology assessments (HTA), and domestic expert consensus, and to propose a revised plan as soon as possible.